News & Press: Patient Safety

Safety Alert: Ranier’s Rx Laboratory Issues Voluntary Recall of All Sterile Compounded Products

Monday, July 30, 2018  
Share |

SIS Patient Safety Alert 07/30/2018: Ranier’s Rx Laboratory Issues Voluntary Recall of All Sterile Compounded Products Within Expiry Due to Lack of Sterility Concerns

This is an important alert from the Spine Intervention Society. SIS sends Patient Safety Alerts when it receives important information regarding products or services that can impact your patients' safety. When the Food and Drug Administration (FDA) issues a safety alert, or a company announces a recall or market withdrawal, the FDA posts the announcement as a public service. Neither SIS, nor the FDA endorse either the product or the company.

ISSUE: Ranier’s Rx Laboratory is voluntarily recalling all sterile compounded drug products within expiry to the hospital or consumer level. This is an update to the Safety Alert issued on July 12, 2018.

These drug products are being voluntarily recalled due to concerns that practices at the pharmacy have the potential to pose a risk of contamination to products that are intended to be sterile. These concerns arose following a routine inspection of the pharmacy by the FDA.

Administration of a non-sterile product that is intended to be sterile by subcutaneous, intramuscular, intravenous or ocular routes of administration may result in a site-specific or systemic infection which in turn may result in hospitalization, significant morbidity, organ damage, or a fatal outcome. The pharmacy has not received any reports of patient complaints or adverse events related to this recall. To date, the FDA is not aware of any adverse events associated with the use of compounded drug products from the pharmacy.  Nor is there any indication that the compounded sterile drug products being recalled are actually contaminated. This voluntary recall is being conducted out of an abundance of caution and to promote patient safety, which is the pharmacy’s highest priority.

BACKGROUND: The recall encompasses compounded sterile drug products, within expiry, that were dispensed between January 17, 2018, and July 10, 2018. The sterile drug products subject to this recall were distributed only within the State of Pennsylvania and directly to customers and/or medical facilities. The recall does not affect the pharmacy’s non-sterile compounded products or retail pharmacy operations.

The pharmacy has notified potentially affected customers of the voluntary recall via U.S. Mail and direct outreach.

RECOMMENDATION: Customers who have received sterile compounded products subject to the recall should stop using and return the product to the pharmacy for a full refund. Consumers with questions regarding this recall can contact Ranier’s Rx Laboratory by calling Jennifer Henry at 724-527-2752, Monday through Friday between 9:00 a.m. and 5:00 p.m., EST. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using these drug products.

The FDA encourages health care professionals and patients to report adverse reactions or quality problems experienced with the use of these products to the FDA’s MedWatch Adverse Event Reporting program by:

  • Completing and submitting the report online; or
  • Downloading and completing the form, then submit it via fax at 1-800-FDA-0178.


Read the FDA MedWatch Safety Alert for further details.

Source: Food and Drug Administration - Accessed 07/30/2018


Contact Us

120 E. Ogden Ave. Ste. 202
Hinsdale, Illinois 60521
P: 630.203.2252
Toll Free: 888.255.0005

© Copyright 2016 Spine Intervention Society Privacy Policy  ::  Legal